Free Trial
LON:SCLP

Scancell Interim Earnings Results & Report

Scancell logo
GBX 84 +2.00 (+2.44%)
As of 11:57 AM Eastern

Scancell reported Interim earnings on January 30, 2025. The company reported EPS of -GBX 13.50.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

Scancell EPS Results

Actual EPS
-GBX 13.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Scancell Interim Earnings FAQ

Scancell (LON:SCLP) reported earnings of -GBX 13.50 per share for Interim. The report was announced on Thursday, January 30, 2025.

Scancell Earnings Headlines

Issue of Equity, Director Dealing & Voting Rights
This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S.

View Scancell Profile